Who is the new Infront and what does it stand for?
Read the following interview about our new market positioning, our product strategy and how you will benefit from it. Kristian Nesbak, CEO of Infront, Florent Grauer as CPO of Infront and Afsheen Azam as Head of Customer Support, Europe at Infront will give you some insights.
Infront announced today that Ramsey Crookall, the Isle of Man’s longest-established independent stockbroker, has gone live with the Infront Professional Terminal, replacing their existing terminals across their trading and analyst desks.
Oslo 10 March 2020 – Infront, the leading European provider of IT solutions for the investment industry, announced today that Davy, Ireland’s leading wealth manager & capital markets adviser, has successfully replaced existing terminals with the Infront Professional Terminal across the group.
The current situation cannot be compared with anything that has happened on the markets in recent decades and no one can predict what challenges we will face in the coming months. In our current newsletter edition we inform you how you can easily access the current financial markets with our Infront Professional Terminal despite home office, how you can minimize credit default risks and much more. Are you interested?
The EMEA Trading Conferenceis Europe’s largest one-day electronic trading event. The event will cover the most pressing issues facing the institutional trading community and provide a neutral platform for buy-side, sell-side, exchanges, vendors and regulators to share their ideas on how the community can continue to collaborate. Designed to appeal to all asset classes, the agenda will maintain a great balance of topics across multiple asset classes.
The event will be held virtually. Further information will follow shortly.
Further information will be available shortly here or under SA Intellidex Stockbroker Awards.
AM TECH DAY is the European market event dedicated to the impact of technological innovation on the asset management industry, gathering asset managers, wealth managers, asset owners, insurers and FinTechs. For its 11th year, the event will be held on 13 October at the Palais Brongniart, Paris.
The health crisis has made it more vital than ever to communicate, talk and work online, effectively boosting the value of all tools that can do this in a fast and secure way. It has also spurred their adoption throughout the asset management industry with the early adopters effectively providing a stress test for the sector.
At the same time, technologies continue to improve, giving professional investors a better handle on the key issues affecting sustainable development and helping them adopt best practice in transparency, equity and security.
Now more than ever, the asset management industry has the means and the opportunity to reinvent itself.
Meet Infront there: Palais Brongniart, 16 Place de la Bourse, at 10:00.
As in previous years, COPS invites to their annual COPS user meeting this year from 22 to 23 October 2020 at the Seehotel Rust in Rust on Neusiedlersee.
The customers can expect a versatile and varied program, ranging from innovations in software solutions, successful project reports to practical application examples.
As a strategic partner, COPS gives us the opportunity to present our company and our solutions and show-case the cooperation with COPS.
You can find further information here...
The SIPUGday focuses since the start on market data and related technologies, services and products in the front, back and middle office. Regulations and their impact on data are also a topic for our audience.
Infront and vwd will be represented on site by Ivo Bieri, Managing Director Switzerland. He will be happy to inform you about the advantages for you of the merger of the two companies in the future. We look forward to a lively exchange with you!
October 27, 2020
We will again be represented at the DKF this year and look forward to your visit to our stand.
Further information will be available here soon or on the official DKF 2020 website.
Further information will be available shortly here or under Quantalys Inside 2020.
11.10.2019 BUSINESS WIRE: Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
BOULDER, Colo. --(BUSINESS WIRE)-- 11.10.2019 --
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement.
'Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting,” said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer. “It is vital that the expansion of available maintenance options continues as maintenance treatments extend the time between chemotherapies. Many women with relapsed ovarian cancer know that they are facing a future of managing their disease as a chronic illness.”
“For too long ovarian cancer treatment options beyond chemotherapy or surgery have been limited, and today’s announcement means that women with ovarian cancer have more choice in their treatment than ever before,” said Annwen Jones, Chief Executive of Target Ovarian Cancer, a United Kingdom ovarian cancer charity. “Target Ovarian Cancer has long campaigned for better treatment for women with ovarian cancer and we are delighted to see this latest development.”
Approximately 6,400 women are diagnosed with ovarian cancer in the UK every year, which equates to roughly 17 every day.2 Despite advancements in treatment and care, more than 4,000 women still die each year from ovarian cancer in the UK.2 Of those treated with surgery and first line chemotherapy, approximately 70% of patients will relapse within the first three years.3
“Inclusion of rucaparib in the CDF as an option for maintenance treatment for patients with recurrent ovarian cancer responding to platinum-based therapy regardless of BRCA mutation status or line of treatment in the relapsed maintenance setting represents a much-needed treatment option for women with recurrent ovarian cancer,” said Professor Jonathan Ledermann, MD, Professor of Medical Oncology, UCL Cancer Institute and UCL Hospitals, London, global Principal Investigator for non-US sites in the ARIEL3 study. “I am pleased that the CDF recommendation includes access for the broad patient population evaluated in the ARIEL3 trial which demonstrated rucaparib to be effective in eligible patients, regardless of their BRCA mutation status, providing a clinically-meaningful median progression-free survival of more than one year across the entire population studied by independent radiological review. This represents a significant step in the effective management of relapsed ovarian cancer in the NHS in England.”
The European Union (EU) conditional marketing authorization is based on data from the pivotal Phase 3 ARIEL3 clinical trial. ARIEL3 successfully achieved its primary endpoint of extending investigator-assessed PFS versus placebo in all patients treated (intention-to-treat, or ITT), population, regardless of BRCA status (median 10.8 months vs 5.4 months).4,5 In addition, it successfully achieved the key secondary endpoint of extending PFS by independent radiological review versus placebo in all patients treated (ITT), regardless of BRCA status (median 13.7 months vs 5.4 months).5 The overall safety profile of rucaparib is based on data from 937 patients with ovarian cancer treated with rucaparib monotherapy in clinical trials.5
“We welcome NICE’s recommendation to make rucaparib available through the CDF to all eligible women in England who may potentially benefit from this important therapeutic option,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “For women with recurrent ovarian cancer, access to new treatments that successfully demonstrate prolonged progression-free survival is essential in the fight against this deadly disease and central to Clovis Oncology’s mission to provide the right drug, to the right patient at the right time.”
About Rubraca® (rucaparib)
Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 that is being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancer (mCRPC), as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.
Rubraca® (rucaparib) European Union (EU) Conditional Marketing Authorization
Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Rubraca is indicated as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with ≥ 2 prior lines of platinum-based chemotherapy, and who are unable to tolerate further platinum-based chemotherapy.
Summary Warnings, Precautions and Safety
Efficacy of Rubraca as treatment for relapsed or progressive EOC, FTC, or PPC has not been investigated in patients who have received prior treatment with a PARP inhibitor. Therefore, use in this patient population is not recommended.
The overall safety profile of rucaparib is based on data from 937 patients in clinical trials in ovarian cancer treated with rucaparib monotherapy. Adverse reactions occurring in ≥ 20% of patients receiving rucaparib were nausea, fatigue/asthenia, vomiting, anaemia, abdominal pain, dysgeusia, ALT elevations, AST elevations, decreased appetite, diarrhoea, thrombocytopenia and creatinine elevations. The majority of adverse reactions were mild to moderate (Grade 1 or 2).
The ≥ Grade 3 adverse reactions occurring in > 5% of patients were anaemia (23%), ALT elevations (10%), fatigue/asthenia (10%), neutropenia (8%), thrombocytopenia (6%), and nausea (5%). The only serious adverse reaction occurring in > 2% of patients was anaemia (5%).
Adverse reactions that most commonly led to dose reduction or interruption were anaemia (20%), fatigue/asthenia (18%), nausea (16%), thrombocytopenia (15%), and AST/ALT elevations (10%). Adverse reactions leading to permanent discontinuation occurred in 10% of patients, with thrombocytopenia, nausea, anaemia, and fatigue/asthenia being the most frequent adverse reactions leading to permanent discontinuation.
During treatment with rucaparib, events of myelosuppression (anaemia, neutropenia, thrombocytopenia) may be observed and are typically first observed after 8-10 weeks of treatment with rucaparib. These reactions are manageable with routine medical treatment and/or dose adjustment for more severe cases. Complete blood count testing prior to starting treatment with rucaparib and monthly thereafter, is advised. Patients should not start rucaparib until they have recovered from haematological toxicities caused by previous chemotherapy (≤ CTCAE Grade 1).
Myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML), including cases with fatal outcome, have been reported in patients who received rucaparib. The duration of therapy with rucaparib in patients who developed MDS/AML varied from less than 1 month to approximately 28 months. If MDS/AML is suspected, the patient should be referred to a haematologist for further investigations, including bone marrow analysis and blood sampling for cytogenetics. If, following investigation for prolonged haematological toxicity, MDS/AML is confirmed, rucaparib should be discontinued.
Further information should be obtained from the Rucaparib Summary of Product Characteristics (SmPC) found here: www.medicines.org.uk/emc/product/10028/smpc.
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Side effects should be reported. See yellowcard.mhra.gov.uk for how to report side effects.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the U.S. and Europe. Please visit www.clovisoncology.com for more information.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management. Examples of forward-looking statements contained in this press release include, among others, statements regarding our plans to launch Rubraca in additional European countries, including the United Kingdom, and to make Rubraca available to additional eligible patients. Such forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from that expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the market potential of Rubraca, including the performance of our sales and marketing efforts and the success of competing drugs and therapeutic approaches, the performance of our third-party manufacturers, our clinical development programs for our drug candidates and those of our partners, and actions by the FDA, the EMA or other regulatory authorities regarding data required to support drug applications and whether to accept or approve drug applications that may be filed, as well as their decisions regarding drug labeling, reimbursement and pricing. Clovis Oncology does not undertake to update or revise any forward-looking statements. A further description of risks and uncertainties can be found in Clovis Oncology’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its reports on Form 10-Q and Form 8-K.
Clovis investor contacts:
Anna Sussman, +1 303.625.5022
Breanna Burkart, +1 303.625.5023
Clovis media contacts:
Lisa Guiterman, +1 301.217.9353
Jake Davis, +44 (0) 203.946.3538
Joanna Sullivan +44 (0) 207.173.4191
10.07.2020 Mynewsdesk: 20 Jahre united-domains
Seit 20 Jahren vertrauen Kunden united-domains, wenn es darauf ankommt, einfach und schnell Domains zu registrieren. Mit einem Jubiläums-Gewinnspiel bedankt sich united-domains und bietet die Chance attraktive Preise zu gewinnen.Seit 20 Jahren steht der Domain-Spezialist aus Starnberg ...
08.07.2020 Mynewsdesk: Digitalisierung in der Baugrube - Kooperation mit Fraunhofer-Institut für Physikalische Messtechnik IPM
Bayernwerk entwickelt App für Geoinformationssysteme – Teil der DigitalisierungsoffensiveGeoinformationssysteme (GIS) spielen eine wichtige Rolle beim Netzausbau und damit für die Energiewende. Je genauer sie Auskunft über die Lage von erdgebundener Infrastruktur geben, umso ...
08.07.2020 Mynewsdesk: Athera reports last patient visit for Phase 2 trial in STEMI patients
Athera Biotechnologies AB, a Swedish biopharmaceutical developer of therapeutic antibodies, announced that the last patient visit has been completed in their Phase 2 study with ATH3G10, a new candidate drug for prevention of heart failure following an acute myocardial infarction. The study ...
06.07.2020 Mynewsdesk: Flughafen Hamburg mit exklusivem Design-Ambiente von BoConcept Hamburg
Ein Gespräch mit Ole Valsgaard, dem Inhaber mehrerer BoConcept-Stores in Hamburg und Hannover, zu der Neugestaltung der VIP-Lounge im Hamburger FlughafenDie 500 qm große VIP-Lounge am Hamburger Flughafen im Terminal 2 bekam in diesem Frühsommer eine Rundum-Erneuerung. ...
02.07.2020 Mynewsdesk: Oliver Kahn ist zurück auf der Paulaner Bank - die '0,0%' steht
Konsequent ohne Alkohol, überzeugend im Geschmack, traditionell gebraut“ – mit diesen Attributen überzeugt Paulaner Weißbier 0,0% seit März Konsumenten, die sich bewusst für das erste komplett alkoholfreie Weißbier aus Bayern entscheiden. Nachdem die ...
02.07.2020 Mynewsdesk: Gespräche zur Stärkung der Sozialpartnerschaft
Die Systemgastronomie steht durch die Corona-Pandemie weiterhin vor großen Herausforderungen. Der Bundesverband der Systemgastronomie e.V. (BdS) und die Gewerkschaft Nahrung-Genuss-Gaststätten (NGG) haben sich deshalb auf Initiative des BdS in der vergangenen Woche zu einem ...
10.07.2020 GlobeNewswire: Lösungen von Lantronix für die Out-of-Band-Verwaltung gewährleisten sicheren Remotezugriff für Rechenzentren und verteilte Arbeitsplätze
Lösungen von Lantronix für die Out-of-Band-Verwaltung gewährleisten sicheren Remotezugriff für Rechenzentren und verteilte Arbeitsplätze Optimierung der Remoteverwaltung von Netzwerk, Servern und Rechenzentren für eine sichere und zuverlässige Geschäftskontinuität IRVINE, Kalifornien, July 10, 2020 (GLOBE NEWSWIRE)...
10.07.2020 GlobeNewswire: Medienmitteilung | MCH Group | Kapitalerhöhung und neuer Investor
Medienmitteilung | MCH Group | Kapitalerhöhung und neuer Investor Finanzielle und strukturelle Stärkung zur Überwindung der Coronakrise und Umsetzung der langfristigen Strategie Die MCH Group will ihre Kapitalstruktur und Aktionärsbasis stärken, um die Folgen der Coronakrise bewältigen und den Prozess der zukunftsorientierten...
10.07.2020 GlobeNewswire: Basilea gibt den Beginn der Angebotsfrist ihres Teilrückkaufsangebots für ihre ausstehenden Wandelanleihen mit Fälligkeit 2022 bekannt
Basilea gibt den Beginn der Angebotsfrist ihres Teilrückkaufsangebots für ihre ausstehenden Wandelanleihen mit Fälligkeit 2022 bekannt NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN Basel, Schweiz, 10. Juli 2020 Nach der Veröffentlichung des...
10.07.2020 GlobeNewswire: Biotalys ernennt Wim Ottevaere in Vorbereitung auf globales Wachstum zum Chief Financial Officer
Biotalys ernennt Wim Ottevaere in Vorbereitung auf globales Wachstum zum Chief Financial Officer Stärkung des Executive Management Teams durch internationale Führungskraft im Finanzbereich GENT, Belgien, und RESEARCH TRIANGLE PARK, North Carolina, July 10, 2020 (GLOBE NEWSWIRE) -- Biotalys NV , ein innovatives Lebensmittel- und...
09.07.2020 GlobeNewswire: Clever Leaves erhält EU-GMP-Zertifizierung (European Union Good Manufacturing Practices)
Clever Leaves erhält EU-GMP-Zertifizierung (European Union Good Manufacturing Practices) Kolumbianischer Betrieb von Clever Leaves erhält als erste medizinische Cannabisanlage aus Lateinamerika EU-GMP-Zertifizierung NEW YORK, July 09, 2020 (GLOBE NEWSWIRE) -- Clever Leaves (das „Unternehmen“), ein führender multinationaler...
09.07.2020 GlobeNewswire: Monument verkündet positive Bohrergebnisse bei den Murchison-Goldprojekten in Western Australia
Monument verkündet positive Bohrergebnisse bei den Murchison-Goldprojekten in Western Australia VANCOUVER, British Columbia, July 09, 2020 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY und FSE: D7Q1) („Monument“ oder das „Unternehmen“) freut sich, die Ergebnisse der Explorationsbohrungen im unternehmenseigenen...